Date: 2013-12-05
Type of information: Development agreement
Compound: rAAVrh10 vectors
Company: Lysogene (France) Regenx Biosciences (USA - MD)
Therapeutic area: Rare diseases
Type agreement: development
licensing
commercialisation
Action mechanism:
Disease: mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome Type A)
Details: * On December 5, 2013, Regenx Biosciences and Lysogene announce that they have entered into an agreement enabling the development and commercialization of products to treat mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome Type A) using NAV rAAVrh10.
Under the terms of the agreement, Regenx granted Lysogene an exclusive worldwide license, with rights to sublicense, to Regenx\'s NAV rAAVrh10 vectors for treatment of MPS IIIA in humans. In return for these rights, Regenx receives payments in the form of an up-front payment, certain milestone fees and royalties on net sales of products incorporating NAV rAAVrh10.
Financial terms:
Latest news:
